LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 1 of total 1

Search options

Article ; Online: Vaccine effectiveness against influenza hospitalisation in adults during the 2022/2023 mixed season of influenza A(H1N1)pdm09, A(H3N2) and B circulation, Europe: VEBIS SARI VE hospital network.

Rose, Angela M C / Pozo, Francisco / Martínez-Baz, Iván / Mazagatos, Clara / Bossuyt, Nathalie / Cauchi, John Paul / Petrović, Goranka / Loghin, Isabela I / Vaikutyte, Roberta / Buda, Silke / Machado, Ausenda / Duffy, Róisín / Oroszi, Beatrix / Howard, Jennifer / Echeverria, Aitziber / Andreu, Cristina / Barbezange, Cyril / Džiugytė, Aušra / Nonković, Diana /
Popescu, Corneliu-Petru / Majauskaite, Fausta / Tolksdorf, Kristin / Gomez, Verónica / Domegan, Lisa / Horváth, Judit Krisztina / Castilla, Jesús / García, Miriam / Demuyser, Thomas / Borg, Maria-Louise / Tabain, Irena / Lazar, Mihaela / Kubiliute, Ieva / Dürrwald, Ralf / Guiomar, Raquel / O'Donnell, Joan / Kristóf, Katalin / Nicolay, Nathalie / Bacci, Sabrina / Kissling, Esther

Influenza and other respiratory viruses

2024  Volume 18, Issue 2, Page(s) e13255

Abstract: We conducted a multicentre hospital-based test-negative case-control study to measure vaccine effectiveness (VE) against PCR-confirmed influenza in adult patients with severe acute respiratory infection (SARI) during the 2022/2023 influenza season in ... ...

Abstract We conducted a multicentre hospital-based test-negative case-control study to measure vaccine effectiveness (VE) against PCR-confirmed influenza in adult patients with severe acute respiratory infection (SARI) during the 2022/2023 influenza season in Europe. Among 5547 SARI patients ≥18 years, 2963 (53%) were vaccinated against influenza. Overall VE against influenza A(H1N1)pdm09 was 11% (95% CI: -23-36); 20% (95% CI: -4-39) against A(H3N2) and 56% (95% CI: 22-75) against B. During the 2022/2023 season, while VE against hospitalisation with influenza B was >55%, it was ≤20% for influenza A subtypes. While influenza vaccination should be a priority for future seasons, improved vaccines against influenza are needed.
MeSH term(s) Adult ; Humans ; Influenza, Human/epidemiology ; Influenza, Human/prevention & control ; Seasons ; Influenza A Virus, H1N1 Subtype/genetics ; Influenza A Virus, H3N2 Subtype/genetics ; Case-Control Studies ; Vaccine Efficacy ; Influenza Vaccines ; Europe/epidemiology ; Hospitalization ; Hospitals ; Pneumonia ; Vaccination
Chemical Substances Influenza Vaccines
Language English
Publishing date 2024-02-23
Publishing country England
Document type Journal Article
ZDB-ID 2274538-5
ISSN 1750-2659 ; 1750-2640
ISSN (online) 1750-2659
ISSN 1750-2640
DOI 10.1111/irv.13255
Shelf mark
Zs.A 6568: Show issues Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)
Database MEDical Literature Analysis and Retrieval System OnLINE

More links

Kategorien

To top